President Joe Biden said Thursday that the U.S. will have enough supply of the COVID-19 vaccine by the end of the summer to inoculate 300 million Americans.
Biden made the announcement at the sprawling National Institutes of Health complex just outside Washington as he visited some of the nation's leading scientists on the frontlines of the fight against the disease. He toured the Viral Pathogenesis Laboratory that created the COVID-19 vaccine now manufactured by Moderna and being rolled out in the U.S. and other countries.
The U.S. is on pace to exceed Biden’s goal of administering 100 million vaccine doses in his first 100 days in office, with more than 26 million shots delivered in his first three weeks.
“That’s just the floor,” Biden said. "Our end goal is beating COVID-19.”
Biden announced on Thursday that the U.S. had secured contractual commitments from Moderna and Pfizer to deliver the 600 million doses of vaccine by the end of July — more than a month earlier than initially anticipated.
“We’re now on track to have enough supply for 300 million Americans by the end of July," he announced.
The pace of injections could increase further if a third coronavirus vaccine from drugmaker Johnson & Johnson receives approval from the Food and Drug Administration.
Speaking with Dr. Anthony Fauci, the nation's top infectious-disease specialist, Biden emphasized that his administration is doing everything possible to increase the vaccine supply and the country's capacity to deliver injections into arms.
“It’s been a hell of a learning process," Biden said.
Biden, wearing a mask, used his remarks to criticize President Donald Trump, saying he inherited “no plan to vaccinate most of the country.”
“It is no secret that the vaccination program was in much worse shape than my team and I anticipated,” he said.
To date, the Biden administration has deployed active-duty troops to help stand up mass vaccination sites in several states, as it looks to lay the groundwork for increasing the rate of vaccinations once more supply is available.
The Viral Pathogenesis Laboratory is led by Dr. Barney Graham, whose team made critical discoveries years ago that laid the groundwork for rapid development of that and other COVID-19 vaccines. Before the pandemic erupted, one of Graham’s research fellows, Dr. Kizzmekia Corbett, had been using those earlier findings to develop a vaccine for MERS, a cousin of COVID-19.
On the tour, Biden was shown the lab bench where researchers sequenced the virus and developed the precursor of the Moderna vaccine.
Armed with their prior research, Corbett and Graham had a head start when Chinese scientists shared the genetic map of the new coronavirus in January 2020. They already knew how to make spike proteins, which coat the surface of the new coronavirus and its MERS relative, that were stable enough to be used as a key vaccine ingredient.
Within days, the NIH had sent instructions to Moderna to brew up doses, and Corbett and her colleagues were setting up the key lab and animal tests that would eventually prove they were on the right track.
Associated Press Medical Writer Lauran Neergaard in Washington contributed to this report.
A subvariant of the omicron COVID-19 variant called BA.2 is causing an outbreak overseas. Now, some health experts worry it could also lead to an increase in COVID-19 cases in the U.S. Dr. Amesh Adalja, infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joins Cheddar News to discuss.
Dr. Alan Kaplin, Chief Scientific Officer of MyMD, joins Cheddar Innovates to discuss how the MYMD-1 is on track to be the first FDA-approved drug to treat aging and age-related diseases.
Tyler Hayes, CEO of Atom Limbs, joins Cheddar Innovates to discuss how the Atom Touch prosthetic is different from other prosthetics on the market, and how the Atom Limbs team of former Apple and Tesla leaders are bringing innovation into this industry.
Nouveau Monde Graphite says it wants to power the sustainable energy revolution. The Canadian company is developing carbon-neutral battery materials to serve the growing EV and cleantech markets and is doing so via a mining and manufacturing operation in Quebec. Eric Desaulniers, founder, president & CEO of Nouveau Monde Graphite, joins Cheddar News' Closing Bell to discuss.
Health experts are warning an even more contagious subvariant of Omicron, known as BA.2, could soon lead to another surge in Covid cases here in the U.S. The variant has already driven cases to skyrocket in China and Europe, which has historically served as a preview to the pattern the U.S. has seen throughout the pandemic. This comes at a time when protection from booster shots is waning for most people who got them. Dr. Jen Caudle, Family Physician & Associate Professor at Rowan University, explains what we can do to protect ourselves against the new variant and how we should act as warnings of another surge rise.
Catching you up on what you need to know Mar 24, 2022, with NATO meeting updates, Ukraine retaking suburbs around Kyiv, the spread of omicron subvariant BA.2 in China, Google Pay launching a third-party billing option, and a 16-year-old is suspected of being the Lapsus$ mastermind behind hacks of Microsoft and others.
Cannabis producer Cresco Labs is acquiring rival Columbia Care in a $2 billion all-stock deal, creating the largest U.S. cannabis company by sales. The deal, which is expected to close in the fourth quarter of 2022, is one of the biggest in the industry's history and would make Cresco the dominant player in a market projected to reach $46 billion in revenue by 2026. Charlie Bachtell, CEO of Cresco Labs, joins Cheddar News' Closing Bell to discuss.
Moderna announced it's seeking emergency use approval for its COVID-19 vaccine from the FDA for children under 6 years old. A former FDA associate commissioner and the president and co-founder of the Center for Medicine in the Public Interest (CMPI) Peter Pitts joined Cheddar News to talk about the timeline, benefits, and risks that come with the approval of the vaccine. "We want to protect their parents and their grandparents and their caregivers and their daycare providers, so it's all about protecting not just the kids but all around the people that are surrounding those kids," he said.
Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers. The company announced early findings Wednesday from a study of children younger than 6.
Catching you up on what you Need to Know on Mar 23, 2022, as NATO meets in Brussels to discuss Ukraine, mortgage rates rise, Justin Trudeau is set to lead Canada until 2025, tornadoes sweep through Louisiana, California may do away with SATs, and a Starbucks in Seattle unionizes.
